English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Niceritrol, a derivative of nicotinic acid, has been used in the treatment of atherosclerotic and obstructive vascular diseases. It was given to patients with facial palsy for 8 weeks or morc in combination with massive doses of ATP and/or steroids used during the initial 2 or 3 weeks.1. Assessment by our Paralysis and Secondary Defect Scorc showed that the results could be classified as'good'or better in 37.2% of the patients in 2 weeks, 54.2% in 4 weeks, 60.0% in 6 weeks and 68.5%in 8 weeks.2. It was striking that 3 of 4 patients with Hunt's syndrome recovered completely within 4 wceks and one patient with severe paralysis for 20 years due to surgical trauma showed a fair recovery.These results indicate that the combination of niceritrol and ATP and/or steroids is effective in the therapy of facial palsy.

Effect of niceritrol combined with other drugs in the treatment of facial palsy.